ASCO’s biggest winners showcased a new era of cancer innovation

ConferencepositivePositive

AI Analysis

Summary

Revolution Medicines, Summit, Akeso, and Eli Lilly presented positive cancer drug data at the 2026 ASCO meeting, with Revolution's pancreatic cancer candidate and Lilly's in vivo CAR T approach demonstrating promising efficacy.

Outcome Details

Full data from Revolution Medicines' pancreatic cancer drug met expectations; Summit and Akeso demonstrated PD-(L)1/VEGF mechanism; Eli Lilly's in vivo CAR T showed positive results

Importance:7/10

Sentiment:

0.85

ASCOconferencepancreatic cancerCAR Toncologydata readout

Related Companies

$RVMD $SMMT $LLY

Read the original article

Published by BioSpace on June 3, 2026 2:54 PM

Read Original